IRCT20170210032478N3CompletedPhase 3
The efficacy of inhaled formoterol on symptom improvement in covid 19 patients
ational Research Institute of Tuberculosis and Lung Diseases0 sites200 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Enrollment
- 200
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 years to 75 years (—)
- Sex
- All
Inclusion Criteria
- •(COVID-19) with according to the clinical manifestations confirmed with CBC, CRP, and Chest radiography or other lab tests
- •Patients who voluntarily sign our consent form.
Exclusion Criteria
- •Comorbidity
- •Saturation less than 93%
- •The presence of symptoms for more than 7 days
- •History of formoterol intolerance
- •cardiac diseases, such as heart failure or arrhythmia
- •Recent history of using inhaled corticosteroids, bronchodilators, and ACE inhibitors
- •Asthma or COPD
- •Heavy Smoker
Investigators
Similar Trials
Completed
Not Applicable
Efficacy of formoterol inhalation in patients with chronic obstructive pulmonary disease: investigation of the effects on the central and peripheral airways starting from immediately after inhalatioChronic obstructive pulmonary disease (COPD)JPRN-UMIN000013318General incorporated association, Academy of Inhalation Methods (AIMs)60
Not yet recruiting
Unknown
Role of Formoterol and Budesonide inhaler in childhood asthmaCTRI/2024/02/062290All India Institute of Medical Sciences, Rishikesh
Withdrawn
Phase 2
Efficacy and Safety of Two Doses of Formoterol Fumarate MDI (PT005) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), Compared to Foradil® Aerolizer® as an Active ControlCOPDNCT01043601Pearl Therapeutics, Inc.
Recruiting
Not Applicable
Efficacy and safety of inhaled formoterol in Japanese COPD patients with %FEV1>=80%Japanese COPD patients with %FEV1>=80%JPRN-UMIN000019118Kanazawa University Hospital30
Completed
Phase 2
Study to Demonstrate Equivalence of Formoterol 12 and 24 µg Delivered Via Two Types of Single Dose Dry Powder Inhalers (Concept1 and Aerolizer)AsthmaNCT00443482Novartis50